Emerald Advisers’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Emerald Advisers’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-126,436	Closed	-$13.6M	–	235
2023 Q1	$13.6M	Sell	126,436 -23,253	-16%	-$2.68M	0.65%	73
2022 Q4	$16.5M	Buy	+149,689	New	+$9.71M	0.8%	56

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Emerald Advisers's RXDX Position: Q2 2023 in Review

Emerald Advisers sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 126,436 shares — an estimated $13.6M sold.

Emerald Advisers first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $16.5M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Emerald Advisers reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Emerald Advisers sold 126,436 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $13.6M.
Emerald Advisers first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Emerald Advisers's Prometheus Biosciences, Inc. Common Stock position peaked at $16.5M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Emerald Advisers's 13F filing for Q2 2023, filed 25 Jul 2023.